NCT06451848View on ClinicalTrials.gov

A Bioequivalence Study of Two Different Dosage Form of Genakumab

PHASE1CompletedINTERVENTIONAL
Enrollment

178

Participants

Timeline

Start Date

June 24, 2024

Primary Completion Date

November 29, 2024

Study Completion Date

January 10, 2025

Conditions
Gouty Arthritis (GA)
Interventions
DRUG

Genakumab Injection (T, Solution for injection)

A single dose of subcutaneous injection of Genakumab（Solution for injection, liquid formulation）200 mg on Day 1

DRUG

Genakumab for Injection (R, Powder for solution for injection)

A single dose of subcutaneous injection of Genakumab（Powder for solution for injection, lyophilized formulation) 200 mg on Day 1

Trial Locations (1)

610000

Chengdu Xinhua Hospital, Chengdu

All Listed Sponsors
lead

Changchun GeneScience Pharmaceutical Co., Ltd.

INDUSTRY

NCT06451848 - A Bioequivalence Study of Two Different Dosage Form of Genakumab | Biotech Hunter | Biotech Hunter